Inside Invitrolize

What we stand for

Invitrolize is a Luxembourg-based biotech company developing advanced human-relevant in vitro models for respiratory toxicology.

Our core technology, ALIsens®, is a patented 3D alveolar lung model that enables the identification and differentiation of respiratory sensitizers and irritants under realistic air–liquid interface exposure conditions.

ALIsens® has already been evaluated by major industrial players across chemicals, pharmaceuticals, tobacco, food, and academia. Based on the robustness and reproducibility of the data generated, we have initiated the OECD standardization pathway, in line with the expected introduction of respiratory toxicology requirements in the EU around 2027/8.

Respiratory sensitization is a major unmet scientific and regulatory need.

Animal testing is increasingly restricted and often poorly predictive, while no validated method currently exists to classify respiratory sensitizers.

ALIsens® fills this gap with a reproducible, human cell–based system designed for regulatory applicability, supporting early hazard identification, reduced R&D attrition, and robust safety data generation.

ALIsens® originates from over ten years of research at the Luxembourg Institute of Science and Technology (LIST) and is protected by international patents.

The model has been submitted to EURL ECVAM and is progressing toward OECD standardization, enabling future use in regulatory frameworks such as REACH (EU) and EPA (US).

Invitrolize serves chemical, pharmaceutical, cosmetics, tobacco, fragrance, and consumer product industries through testing services and the supply of ready-to-use inserts to CROs and in-house laboratories, with the objective of setting the global standard for animal-free respiratory sensitization testing.

Setting the standard in respiratory sensitization.

Invitrolize’s ALIsens® is a patented human 3D alveolar in vitro model designed to identify and differentiate respiratory sensitizers from irritants under realistic air–liquid interface exposure.

Developed for reproducibility and regulatory applicability, the model supports regulatory submissions.

Anticipate regulatory expectations and address respiratory sensitization requirements early with our technology.

Arno Gutleb

CEO

Request a Demo

Asier Sesma

COO

Talk to us

Sabina Burla

CSO

Giovanna Radicchio

Biotechnologist

Careers

Join Invitrolize and help hape the future of standard of respiratory safety testing.

Let us get to know you.
Apply here

What they say about Invitrolize

Invitrolize provides an exciting opportunity to assess challenging chemicals for challenging endpoints in respiratory toxicity with human-relevant approaches. They are grounded in science while having a clear view of regulatory application to advance toxicology, and we are excited to work with them.

Kristie Sullivan, MPH, Vice President for Research Policy

FOR CROs

Offer a high-value regulatory endpoint without developing the method yourself. ALIsens® enables CROs to expand their inhalation toxicology portfolio with respiratory sensitization testing designed for regulatory use.

Add respiratory sensitization to your service offering.
No multi-year assay development or validation.
Regulatory-driven, OECD-aligned technology.
Clear differentiation in tenders and client pitches.
New high-margin revenue streams.

Explore the CRO Partner Model

FOR INDUSTRY

Identify respiratory sensitization risk early and generate human-relevant data trusted by regulators. ALIsens® helps industrial companies avoid late-stage failures, regulatory delays, and unnecessary R&D losses.

Early identification of respiratory sensitizers.
Differentiation between sensitizers and irritants.
Human-relevant, animal-free data.
Support for regulatory submissions.
Reduced attrition and portfolio risk.

See How Industry Uses ALIsens®